Do we need routine integrase resistance testing before starting . . . Oral second-generation integrase strand transfer inhibitors are now anchor drugs of antiretroviral therapy (ART) globally due to their high resistance barriers In high-income settings, guidelines recommend routine protease and reverse transcriptase resistance testing before ART initiation but suggest routine integrase resistance testing only for individuals at elevated risk of integrase
Predictors of treatment-emergent resistance to dolutegravir Integrase strand transfer inhibitor (INSTI)-based regimens became a first-line treatment for HIV worldwide in 2018, with 93% of people with HIV who are on antiretroviral therapy (ART) estimated to be taking dolutegravir-based regimens as of 2023 Since the genetic barrier to resistance of dolutegravir is not impenetrable, rising rates of dolutegravir resistance among those with virological
HIV-1 Integrase - Cal Lutheran The integrase protein removes two nucleotides from each 3' end of this viral DNA, leaving recessed CA OH's at the 3' ends (B) In a second step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target DNA at the site of integration The 5' ends are produced by integrase-catalyzed
The Integrase: An Overview of a Key Player Enzyme in the . . . - PubMed The highly conserved virus-encoded Integrase enzyme (IN; EC 2 7 7 49) catalyzes such a process by means of two consecutive reactions named 3'-processing (3-P) and strand transfer (ST) The Authors report and discuss the major discoveries and advances which mainly contributed to the development of Human Immunodeficiency Virus (HIV) -IN targeted
Susceptibility to lenacapavir, fostemsavir and broadly neutralizing . . . Surveillance studies of Transmitted Drug Resistance (TDR) are crucial in tracking the evolution of HIV epidemiology Our aim was to investigate TDR to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INIs), as well as to new drugs: lenacapavir, fostemsavir
HIV drug resistance in the era of contemporary antiretroviral therapy . . . Appropriate clinical assessment and management of HIV drug resistance remain important with contemporary antiretroviral therapy (ART) to ensure people living with HIV (PLWH) can continue to achieve lifelong viral suppression (<50 copies mL plasma) 1,2 Resistance will almost inevitably develop to any effective HIV drug used in isolation but is markedly reduced with the use of multidrug regimens
Short Communication: Integrase Strand Transfer Inhibitors Drug . . . Occurrence of major and accessory INSTI-resistance mutations among HIV-1 patients in Puerto Rico (A) Shows the observed frequency of the integrase mutations Q148HKR, G140S, N155H, S147G, E138EA, and Y143R on our studied samples (B) Frequency of integrase accessory mutations D232DN, T97TA, E157Q, and G163GART detected in patient samples
(PDF) Santos et al 2015 - Academia. edu Abstract Objectives: We evaluated the HIV-1 subtype diversity, clinical, genetic and epidemiological profiles of a cohort of long-term non-progressor (LTNPs) followed-up at a referral hospital in southern Brazil Methods: This prospective study
Integrase enables synthetic intercellular logic via bacterial . . . Ba et al present a versatile strategy for integrase-mediated intercellular DNA messaging and regulation, combining bacterial conjugation-based horizontal gene transfer with programmed genetic circuits This approach enables DNA messaging, logic processing, and phenotype modulation in hierarchical E coli strains, offering new avenues for microbial community programming
geno2pheno-THEO on a Large Clinical Database - JSTOR cently licensed coreceptor antagonists and integrase inhibitors have just entered clinical practice, combina-tions of nudeoside nucleotide reverse-transcriptase in- ple, geno2pheno [resistance] [1] andVirtualPhenotype [2] apply methods from statistical learning to predicting in vi-
HIV Drug Resistance Database - Stanford University HBVseq accepts user-submitted HBV RT sequences, determines their genotypes, and compares them to a genotype consensus reference sequence The differences between the submitted sequence and the consensus reference sequence are used as query parameters for interrogating a local HBV drug resistance database (HBVrt DB) to retrieve the prevalence of each mutation according to genotype and treatment